Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity of the Japanese encephalitis vaccine IC51 (JE-PIV)
2005-000253-29Phase 3Completed
- Sponsor
- Intercell AG
- Start
- Jun 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE), sponsored by Intercell AG. Primary endpoints: Primary immunogenicity at 24 months and Long-term immunogenicity up to 60 months. Started Jun 2005; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on 2005-000253-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000253-29.